Maruti Suzuki don’t promise 100% production levels in Q2
Thu, Aug 18, 2022 8:25 PM

Maruti Suzuki don’t promise 100% production levels in Q2

A Flip by Farha
Get it on Google Play
Shashank Srivastava, senior executive director, marketing & sales at Maruti Suzuki India Limited (MSIL) said the semiconductor supplies have reached 95% levels; feeling a gradual recovery in the company’s monthly output. However, he said, the situation may remain the same for the entire second quarter of FY23 as chip supplied haven’t reached 100% yet.

More great flips

Gifty Nifty rises 30 points; here's the trading setup for today's session!

Gifty Nifty rises 30 points; here's the trading setup for today's session!

Equity markets continued their winning streak for the sixth consecutive day on Tuesday. Analysts said the global and domestic markets made a smart comeback as investors remained convinced that the rate-hike cycle has ended. Going forward, investors will take cues from US Service PMI and Jolt Jobs data, said Siddhartha Khemka, Head - Retail Research, Motilal Oswal.

Open Flip
Eicher faces a Himalayan challenge in H2; Hero MotoCorp, Bajaj Auto!

Eicher faces a Himalayan challenge in H2; Hero MotoCorp, Bajaj Auto!

Eicher Motors has long been synonymous with the premium motorcycle segment in India, maintaining a market share of about 90 percent. It has held an undisputed leadership position in the over 250cc sector for more than a decade. However, this dominance is currently facing a potential challenge as two established players seek to make inroads into the market.

Open Flip
Sun Pharma subsidiary seals licensing agreement with Aclaris Therapeutics!

Sun Pharma subsidiary seals licensing agreement with Aclaris Therapeutics!

Sun Pharmaceutical Industries, Inc., on December 6, announced that it has entered into a licensing agreement with Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company specialising in the development of innovative drugs for immuno-inflammatory diseases. Under the terms of the agreement, Aclaris has exclusively granted Sun Pharma the rights to specific patents.

Open Flip

Join our Smart Investment Community

More than 1 Million users are using FlipItMoney to stay updated about the business and finance world! Join FlipItMoney now and take smart investment decisions!
Icon